Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

Pulse Biosciences Appoints Edward Ebbers as Vice President and General Manager of Dermatology Products

Pulse Biosciences,Inc.
Posted on: 24 Aug 16

Pulse Biosciences, Inc., (NASDAQ:PLSE), a medical technology company developing a proprietary therapeutic treatment platform based on Nano-Pulse Electro-Signaling, today announced that it has appointed Edward Ebbers, an experienced medical technology executive, as Vice President and General Manager of its dermatology products.

Ebbers brings more than 35 years of senior leadership and general management experience with major dermatology, pharmaceutical and device brands including Zeltiq Aesthetics, Thermage, Penederm Dermatologics, and most recently as Chief Commercial Officer and Vice President of Marketing at Capnia. In these roles, he led worldwide product development, marketing and sales.

“We are pleased to have Ed join our team and lead Pulse Biosciences’ efforts in dermatology. As we ready our PulseTx™ platform for pilot clinical studies and a planned 510(k) submission, Ed is uniquely qualified to assemble a team of key opinion leaders to guide and execute pilot studies and identify clinical applications for entry into the dermatology market,” said Darrin Uecker, Pulse Biosciences’ President and Chief Executive Officer. “Our ability to attract an executive of Ed’s caliber and track record in dermatology is a validation of our platform’s potential in this market.”

“I am encouraged by the extensive scientific body of evidence demonstrating the unique potential of the Pulse Biosciences’ platform to stimulate cell behavior in various tissue types and skin conditions,” said Mr. Ebbers. “Our clinical studies and product development efforts will build on this foundation to expand advanced treatment options for dermatologists and their patients.”

About Pulse Biosciences

Pulse Biosciences (NASDAQ:PLSE) is a medical technology company developing a therapeutic tissue treatment platform based on Nano-Pulse Electro-Signaling, a proprietary bioelectronics cell signaling technology. Published pre-clinical studies have shown that a single, brief exposure of Nano-Pulse Electro-Signaling to target tissue initiates a cascade of events within cells and in the surrounding microenvironment that results in apoptosis (cell death) and the priming of a durable adaptive immune response. Pulse Biosciences is pursuing a variety of applications for its technology that exploits the technology’s unique biologic effect in immuno-oncology, dermatology, aesthetics, and veterinary medicine. Clinical studies are being planned using the first commercial system designed to support a broad array of electrodes for use in superficial, minimally-invasive, and open surgical procedures. More information is available at

View source version on

Business Wire

Last updated on: 24/08/2016

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.